The guardians' perspective on paediatric cancer treatment in Malawi and factors affecting adherence

2008 ◽  
Vol 51 (5) ◽  
pp. 639-642 ◽  
Author(s):  
Trijn Israëls ◽  
Chawanangwa Chirambo ◽  
Huib Caron ◽  
Jan de Kraker ◽  
Elizabeth Molyneux ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Paediatric Cancer ◽  
Factors Affecting

scholarly journals P9 A study to investigate the impact of the COVID-19 pandemic on paediatric cancer patients: an international, multicentre, observational cohort study (COVIDPaedsCancer)

BJS Open ◽  
2021 ◽  
Vol 5 (Supplement_1) ◽  
Author(s):  
◽  
Soham Bandyopadhyay
Keyword(s):  
Cohort Study ◽  
Cancer Treatment ◽  
Childhood Cancer ◽  
Multivariate Logistic Regression Analysis ◽  
Global Health Research ◽  
Cancer Outcomes ◽  
Paediatric Cancer ◽  
Cancer Management ◽  
Anti Cancer ◽  
The Impact

Abstract Introduction Childhood cancers are a leading cause of non-communicable disease deaths for paediatric patients around the world. The COVID-19 pandemic may have impacted on global children’s cancer services, which can have consequences for childhood cancer outcomes. The Global Health Research Group on Children’s Non-Communicable Diseases (Global Children’s NCDs) is currently undertaking the first international study to determine the variation in paediatric cancer management during the COVID-19 pandemic, and the short to medium term impacts on childhood cancer outcomes. Methods and analysis This is a multicentre, international, cohort study that will use routinely collected hospital data in a de-identified and anonymised form. Patients will be recruited consecutively into the study, with a 12 -month follow-up period. Patients will be included if they are below the age of 18 years and undergoing anti-cancer treatment for the following cancers: Acute lymphoblastic leukaemia, Burkitt’s Lymphoma, Hodgkin's lymphoma, Wilms Tumour, Sarcoma, Retinoblastoma, Gliomas, Medulloblastomas and Neuroblastomas. Patients must be newly presented or be undergoing active anti-cancer treatment from the 12th March 2020 to the 12th December 2020. The primary objective of the study is to determine 30- and 90-day all-cause mortality rates. This study will examine the factors that influenced these outcomes. Chi-squared analysis will be used to compare mortality between low and middle-income countries and high-income countries. Multilevel, multivariate logistic regression analysis will be undertaken to identify patient-level and hospital-level factors affecting outcomes with adjustment for confounding factors. Ethics and dissemination At the host centre, this study was deemed to be exempt from ethical committee approval due to the use of anonymised registry data. At other centres, participating collaborators have gained local approvals in accordance with their institutional ethical regulations. Collaborators will be encouraged to present the results locally, nationally, and internationally. The results will be submitted for publication in a peer reviewed journal.

An observational study of cancer treatment-induced dental abnormalities in paediatric cancer patients

2015 ◽  
Vol 3 (4) ◽  
pp. 228
Author(s):  
Kaberi Das ◽  
Munlima Hazarika ◽  
Manigreeva Krishnatreya ◽  
AmalChandra Kataki
Keyword(s):  
Observational Study ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Paediatric Cancer ◽  
Dental Abnormalities

An Orientation to Implementation Science in Cancer

2018 ◽  
Author(s):  
David A. Chambers ◽  
Wynne E. Norton ◽  
Cynthia A. Vinson
Keyword(s):  
Risk Factors ◽  
Cancer Treatment ◽  
Implementation Science ◽  
Clinical Examination ◽  
Care Delivery ◽  
Scientific Research ◽  
Prevention Programs ◽  
Factors Affecting ◽  
Prevention And Treatment ◽  
The Subject

THE ROOTS of implementation science (IS) in cancer in some sense date back to the earliest days of uncovering cancer’s etiology, diagnosis, prevention, and treatment, although it was not called that. Indeed, unlocking the mysteries of cancer and determining effective ways to intervene began not in the lab but, rather, the clinic. As Mukherjee recounted in the seminal work, The Emperor of All Maladies, 1 cancer had been the subject of clinical examination for centuries, and the drive to optimize care began in those early days. As opposed to the largely separate worlds of research discovery and care delivery that exist today, scientific research and cancer treatment coexisted. In addition, epidemiologic observations of risk factors affecting oncogenesis developed targets for what types of prevention programs needed to be implemented. Naturally, the challenges of what exactly to implement and how best to implement have been with us throughout time.

Factors Affecting Workload of Cancer Clinical Trials: Results of a Multicenter Study of the National Cancer Institute of Canada Clinical Trials Group

2002 ◽  
Vol 20 (2) ◽  
pp. 545-556 ◽  
Author(s):  
Kathyrn Roche ◽  
Nancy Paul ◽  
Bobbi Smuck ◽  
Marlo Whitehead ◽  
Benny Zee ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Data Collection ◽  
Cancer Treatment ◽  
Multicenter Study ◽  
National Cancer Institute ◽  
Phase Iii ◽  
Study Phase ◽  
Factors Affecting ◽  
Clinical Research Associates

PURPOSE: Increasingly, cancer treatment centers need to be able to estimate specific costs and resources associated with clinical trials. Because the time requirements of trial coordination and data collection are not well known, the Clinical Research Associates (CRA) Committee of the National Cancer Institute of Canada Clinical Trials Group carried out a multicenter study to measure trials’ task times and evaluate the effects of certain factors. METHODS: A data collection instrument was designed and validated before its implementation in the study. Eighty-three CRAs from 24 cancer treatment institutions across Canada collected timing observations of 41 tasks (156 subtasks). Information from all stages of trials activity (protocol management, eligibility and entry, treatment, and follow-up and final stage) was obtained, from initial negotiations to follow-up after study closure. RESULTS: After controlling for stage, phase and sponsor were found to be significant independent factors. Analysis within the stages showed similar patterns. New drug inclusion as a factor was confounded with phase. Industry-sponsored studies had significantly higher overall mean times than did local and cooperative group studies. Early-phase studies required more time than did phase III trials. External sponsorship of any kind increased CRA time more than that necessary for locally coordinated studies, except during the protocol management stage. The burden of a phase I study increased to greater than average once underway and accruing patients. CONCLUSION: Our data demonstrated that sponsor and study phase are important factors to be taken into consideration when estimating clinical trial costs and resource use.

scholarly journals Parental involvement in paediatric cancer treatment decisions

2009 ◽  
Vol 19 (5) ◽  
pp. 621-630 ◽  
Author(s):  
K. MCKENNA ◽  
J. COLLIER ◽  
M. HEWITT ◽  
H. BLAKE
Keyword(s):  
Parental Involvement ◽  
Cancer Treatment ◽  
Treatment Decisions ◽  
Paediatric Cancer

scholarly journals The role of hexokinase in cancer

2020 ◽  
Vol 74 ◽  
pp. 144-150
Author(s):  
Paulina Stachyra-Strawa ◽  
Paweł Cisek ◽  
Michał Janiszewski ◽  
Ludmiła Grzybowska-Szatkowska
Keyword(s):  
Cancer Treatment ◽  
Cancer Cells ◽  
New Drugs ◽  
Hexokinase Ii ◽  
Factors Affecting ◽  
Tract Cancer ◽  
Cancer Breast ◽  
Potential Benefits ◽  
High Level

A thorough understanding of the processes occurring in cancer cells is necessary to make cancer treatment as effective as possible. Changes in cellular metabolism in relation to normal cells are considered particularly important. One of the most interesting and promising areas is glucose metabolism and the factors affecting this process, with special emphasis on the potential role of hexokinases, especially the isoform II of this enzyme. Hexokinases (HK) are transferase enzymes involved in the process of glycolysis. Hexokinase II (HK II) plays an important role in initiating and maintaining the glycolysis process at a high level of efficiency, which is crucial for the growth and proliferation of cancer cells. An increase in the number of copies of the HK II gene and increased transcription of this enzyme resulting in the suppression of apoptosis and the enhancement of cell proliferation have been found in tumor cells. Hexokinase II also participates in the Crabtree effect by affecting the amount of ATP and thus the efficiency of the Ca2+ removal process outside the cell membrane by Ca2+ ATPase. Overexpression of HK II has thus far been found in pancreatic cancer, gastric cancer, breast cancer, squamous cell carcinoma of the larynx, glioblastoma multiforme, ovarian cancer and biliary tract cancer, indicating the possible key role of this enzyme in their formation and progression and providing the basis for seeking potential benefits of cancer treatment using HK II as a target of new drugs.

Factors Affecting Sexual Function of Breast Cancer Women After Receiving Cancer Treatment

2013 ◽  
Vol 13 (2) ◽  
pp. 85 ◽  
Author(s):  
Hye Sun Byun ◽  
Bok Yae Chung ◽  
Gyung Duck Kim ◽  
Kyung Hae Kim ◽  
Eun Hee Choi
Keyword(s):  
Breast Cancer ◽  
Sexual Function ◽  
Cancer Treatment ◽  
Factors Affecting

Parental traumatic stress during and after paediatric cancer treatment

2005 ◽  
Vol 44 (4) ◽  
pp. 382-388 ◽  
Author(s):  
Annika Lindahl Norberg ◽  
Frank Lindblad ◽  
Krister K. Boman
Keyword(s):  
Cancer Treatment ◽  
Traumatic Stress ◽  
Paediatric Cancer

Endocrinologist perceived factors affecting the transition of thyroid cancer patients from specialist to primary care post-cancer treatment in Ontario, Canada

Thyroid ◽  
2020 ◽  
Author(s):  
Neha Janmohamed ◽  
Phillip Segal ◽  
Annmarie Corrado ◽  
Aisha Lofters ◽  
Patricia Nguyen ◽  
...  
Keyword(s):  
Primary Care ◽  
Thyroid Cancer ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Factors Affecting
Sign in / Sign up

Export Citation Format

Share Document